For many people exploring treatment for pancreatic cancer, the priority is finding a system that can move fast without sacrificing precision and provide substantial outcomes. Pancreatic tumors are typically managed under time pressure, yet the right plan depends on high-quality imaging, expert pathology, and coordinated decisions about surgery, systemic therapy, and supportive care.<ref>2</ref>

Roughly 20,230 people were diagnosed in 2020 in Germany, which is one reason German centers have substantial real-world experience with the disease.<ref>1</ref> For international patients, the practical advantage is that many providers have established pathways for cross-border care.

Doctors Discussing Pancreatic Cancer Treatment in Germany In this article, we will translate that system into a clear patient journey: what distinguishes the country from other destinations, the available pancreatic cancer treatments in Germany, and how therapies are typically selected by stage, with German specs, results, and insights. Here, we explore hospitals and dive into budget questions so readers can, with evidence, judge whether Germany is the right destination for pancreatic cancer treatment abroad.

For patients seeking pure medical information about pancreatic cancer, read our comprehensive disease-based guide.

Treatment Types Used in Germany

Now, we guide patients seeking pancreatic cancer care through the options Germany offers. In addition to the explanation, our team highlights the data and statistics from German research. This helps navigate pancreatic cancer treatment in Germany, where the country has particular expertise in a specific option.

Pancreatic Cancer Surgery in Germany

Surgery is the primary potentially curative choice for pancreatic malignancy, but it is only effective when the tumor can be completely removed, ideally with “clear margins.”<ref>3</ref> In Germany, pancreatic surgeries are usually performed in specialized units and are reviewed in multidisciplinary tumor boards.<ref>4</ref> There are strong policies and quality incentives encouraging care to be directed toward higher-volume providers. For instance, the Federal Joint Committee has increased the minimum annual case volume for complex pancreatic surgeries from 10 to 20 procedures per hospital.<ref>5</ref><ref>6</ref>

Whipple procedure In 2019, the country recorded 12,034 pancreatic surgeries (11,594 cases), averaging 20 per hospital.<ref>6</ref> This data underscores the importance of patients inquiring specifically about a center’s experience with pancreatic cases.

Potentially Curative Surgeries

Pancreatic operation aims to remove both the tumor and the nearby lymph nodes in a single operation when imaging indicates that the cancer can be surgically removed (or is sometimes borderline resectable, requiring planned vascular reconstruction).<ref>7</ref> In practice, teams in Germany often incorporate surgery into a comprehensive treatment plan, which may include systemic therapy before or after the surgery, depending on the tumor's stage and biology.<ref>8</ref>

Pancreaticoduodenectomy. The Whipple procedure is most often used for tumors in the head of the pancreas. It removes the pancreatic head plus adjacent structures (typically the duodenum and part of the bile duct, often the gallbladder, and sometimes part of the stomach), followed by reconstruction to restore digestion.<ref>7</ref> In nationwide German analyses (2010–2020), pancreaticoduodenectomy was the most common pancreatic resection (61.2%).<ref>9</ref> This experience, along with several German hospitals highlighted in the European Whipple procedure ranking, highlights the country's significant advantage.
Pancreatectomy. It is a broader category that includes different operations depending on tumor location: distal pancreatectomy (removes the left side of the pancreas, often with the spleen, depending on tumor involvement) and total pancreatectomy (removes the entire pancreas). German outcome data illustrate how surgical extent influences risk. A large Heidelberg study of distal pancreatectomy (2001–2020) reported an overall 90-day mortality of 1.6%, with mortality rising stepwise as the extent of additional resections increased (e.g., arterial resection category, up to 8.7%).<ref>10</ref>

Robotic Pancreatic Cancer Surgery in Germany

Robotic-assisted pancreatic surgery, commonly performed with the da Vinci Xi system, is a type of minimally invasive surgery. In this procedure, the surgeon operates from a console, controlling robotic instruments through small incisions.<ref>11</ref> German medical centers primarily utilize robotics to address the technical limitations of standard laparoscopy during intricate steps, such as dissection around major blood vessels and reconstruction of pancreatic and bile duct connections.<ref>12</ref><ref>13</ref>

International consensus guidelines indicate that, in experienced hands, robotic techniques typically result in less blood loss and shorter hospital stays than open surgery for both distal pancreatectomy and pancreatoduodenectomy.<ref>14</ref> Therefore, such operations is on demand for internationals seeking pancreatic cancer treatment in Germany.

Robotic Pancreatic Cancer Surgery in Germany

Showcasing the German experience in robotic pancreatic cancer surgery, a prospective observational study from University Hospital Charite in Berlin was conducted between 2017 and 2020. It reported 129 robotic pancreatic resections using the da Vinci Xi system. Conversion to open surgery occurred in 8–11% of cases. Median postoperative hospital stay was 11–12 days, and 90-day mortality was 3-5%.<ref>15</ref>

A German report on the first 101 consecutive robotic pancreatic resections found significant improvements in operating time from the first to the second half of the cases. The documented 30-day mortality rate in this series was 5.6% for robotic pancreaticoduodenectomy, while there were no reported deaths (0%) for total and distal pancreatectomies in that group.<ref>12</ref>

Palliative Procedures

When a tumor is unresectable (locally advanced with critical vessel involvement) or metastatic, surgery may still be used palliatively. It aims not to cure but to relieve symptoms and prevent complications, especially when endoscopic or radiologic options are unsuitable or have failed.<ref>16</ref> Common palliative surgical options in Germany include:

Biliary Bypass. Hepaticojejunostomy for obstructive jaundice when stenting is not feasible or repeatedly fails.<ref>17</ref>
Gastric Bypass. Gastrojejunostomy for duodenal obstruction (or a “double bypass” when both the bile duct and the gastric outlet are threatened).<ref>16</ref>
Staging Laparoscopy. Exploration surgery is performed when imaging is uncertain, and the team needs to confirm resectability safely.<ref>18</ref>

Germany-specific registry data (StuDoQ|Pancreas) provide a realistic perspective on the risks and trade-offs of palliative surgery. In an analysis conducted from 2013 to 2018, the overall 30-day mortality rate was 4.9%, and major complications occurred in 16.5% of palliative surgical cases. Notably, major complications were associated with a decreased likelihood of patients receiving planned chemotherapy afterward, a vital consideration in palliative care settings.<ref>19</ref>

Systemic Approach

Systemic treatment refers to medicines that circulate through the bloodstream to treat cancer cells throughout the body. It is the backbone of care for most patients with pancreatic adenocarcinoma.<ref>3</ref> Systhemic medications are increasingly used around surgery as a neoadjuvant or adjuvant approach in selected cases.<ref>20</ref>

In Germany, systemic regimens are largely aligned with the national S3 guideline framework, but are individualized based on performance status, biomarker profile, and treatment intent.<ref>8</ref><ref>20</ref>

Cytotoxic Chemotherapy

This is a “classic” chemotherapy approach. Such drugs target rapidly dividing cells, including cancer cells. If you are fit enough for a more intensive regimen, German guideline-based care commonly uses FOLFIRINOX (a multi-drug combination) or NALIRIFOX (a newer option).<ref>20</ref><ref>21</ref>

Chemotherapy approach for pancreatic cancer in Germany For patients, when a more intensive regimen is not suitable (because of overall condition, side-effect risk, or preference), German practice often uses gemcitabine-based chemotherapy, especially gemcitabine + nab-paclitaxel. The S3 guideline explicitly recommends this combination for appropriate patients and also notes that gemcitabine-based combinations are an option when intensive regimens are not tolerated or not preferred.<ref>20</ref><ref>22</ref>

Treatment is typically delivered as outpatient infusions in oncology day units. Doctors monitor closely (blood tests, symptom checks, and periodic imaging) and adjust doses if side effects become limiting.

The goal for systemic pancreatic cancer treatment in Germany may be tumor shrinkage (sometimes to enable surgery or in combination with another therapy), depending on stage and resectability. It may also be used for disease control and/or symptom relief, especially in stage 4 pancreatic cancer.<ref>3</ref><ref>20</ref>

Targeted Therapy

Targeted therapy is only relevant when the tumor has a specific “target” (a gene change, mutation) that a drug can act on.<ref>23</ref> Many larger centers in Germany increasingly use molecular testing to identify such situations, particularly when standard options are limited.<ref>24</ref>

PARP Inhibitor. For some patients with germline BRCA-mutated metastatic disease whose cancer has not progressed on platinum chemotherapy, maintenance treatment with a PARP inhibitor (such as Olaparib) can help keep the cancer under control for longer, according to clinical trial evidence, and this approach is discussed in the German guideline’s molecular subgroup section.<ref>20</ref><ref>25</ref>
KRAS G12C Inhibitor. The German guideline notes that after all standard options are exhausted, treatment with a KRAS G12C inhibitor may be considered.<ref>24</ref> The practical reality is that this is generally not a routine, widely approved track and may require an individual application (“off-label” approach).

Targeted Therapy for Pancreatic Cancer Patients may be advised to undergo tumor molecular profiling and, in some cases, genetic (germline) testing. If a hereditary mutation is suspected or identified, German policies typically recommend genetic counseling.<ref>20</ref> It’s important to note that targeted therapy is not inherently superior; it is effective only when the appropriate target is present.

The experience of the West German Cancer Center Essen highlights the actual yield of actionable findings in pancreatic cancer patients: 17.9% of the profiled patients had actionable molecular alterations. Among those, 29% received targeted treatment based on molecular information, and a small group achieved remarkable responses that lasted over nine months.<ref>26</ref> While these results do not represent the entire population, they underscore why German hospitals prioritize structured molecular testing for selected patients.

Immunotherapy

Immune drugs for pancreatic cancers are not a standard treatment because most tumors are immunologically “cold.”<ref>27</ref><ref>28</ref> Pancreatic cancer immunotherapy in Germany is primarily restricted to specific biomarkers and is often discussed in expert tumor boards.

Immunotherapy for pancreatic cancer The German approach indicates that checkpoint inhibitor immunotherapy may be used after other treatment options have been exhausted in cases where the tumor exhibits dMMR (mismatch-repair deficiency) or MSI-H (high microsatellite instability). It also notes that this situation is uncommon, occurring in less than 1% of pancreatic cancer cases.<ref>29</ref> Therefore, appropriate testing, including pathology-based MMR testing and/or MSI testing, is essential for selecting suitable patients.

Checkpoint inhibitors are currently not approved in Europe for pancreatic tumors specifically. As a result, immunotherapy for pancreatic cancer in Germany is often pursued through clinical trials or individualized off-label application at some hospitals.

Radiation-Based Solutions

Radiation therapy is not a “default” part of German pancreatic cancer treatment. It is usually used selectively when the tumor is locally advanced (unresectable), or when oncologists want better local control after initial chemotherapy, or when symptoms require rapid relief.<ref>30</ref>

Real-world German data reflect this selective use: in a cohort of 23,339 patients diagnosed in 2010–2017, about 4% received radiotherapy within the first year after diagnosis.<ref>31</ref>

Conventional External-Beam Radiotherapy

This is the “classic” form of radiotherapy used in many German pancreatic cancer treatment strategies, delivered over several weeks, often alongside chemotherapy, to control the primary tumor and relieve symptoms when surgery is not possible.

External Beam Radiation Therapy. EBRT is the umbrella term for radiation delivered from outside the body (e.g., a linear accelerator). In Germany, it is typically planned with CT (and often MRI/PET information), with careful contouring of the pancreatic tumor and nearby organs (duodenum, stomach, bowel). It is most commonly used as part of chemoradiation in locally advanced or unresectable disease, or for symptom relief (pain, bleeding, obstruction) when palliative care is the primary goal.
Intensity-Modulated Radiation Therapy. IMRT is an advanced form of EBRT that shapes the dose more precisely around complex anatomy. It is particularly relevant for pancreatic tumors that sit millimeters from sensitive bowel. A German-led randomized phase II program (PARC) reported local control rates of 76.6% and 68.9% at 1 and 2 years.<ref>32</ref>
Image-Guided Radiation Therapy. IGRT involves repeating imaging procedures to confirm the patient's position and reduce the risk of missing the target. This is particularly important in the treatment of pancreatic cancer, where internal organs can shift both during the setup phase and throughout the treatment itself. A German study on adaptive MR-guided radiotherapy for abdominal lesions found that the violation of dose constraints increased significantly, from 6.9% with the adapted plan to 30.2% with the pre-irradiation distribution.<ref>33</ref> This dramatic rise was attributed to intrafraction movement.

High Precision Radiotherapy

This group aims to deliver a higher, more tumor-focused dose in fewer sessions (or via specialized placement), while minimizing exposure to the duodenum and stomach. In Germany, these approaches are typically reserved for carefully selected patients (often after systemic therapy) and are usually decided by multidisciplinary tumor boards.<ref>34</ref>

Stereotactic Body Radiation Therapy. SBRT delivers a high radiation dose in only a few sessions, with very tight safety margins, so controlling tumor motion due to breathing is essential.<ref>35</ref><ref>36</ref> In Germany, SBRT is commonly delivered with dedicated high-precision systems, including robotic CyberKnife platforms (as well as advanced LINAC-based stereotactic systems).<ref>37</ref><ref>38</ref>
Hypofractionated IMRT. Hypofractionated radiation sits between “standard” IMRT and SBRT: fewer sessions than conventional courses, but typically not as extreme as SBRT. The clinical logic in Germany is to shorten overall treatment time while maintaining bowel safety.
Intraoperative Radiotherapy. IORT is utilized in specific surgical scenarios, such as isolated local pancreatic cancer recurrence or experimental endoscopic techniques. A study from Heidelberg that combined surgery with IORT + EBRT, demonstrating how intraoperative-type boosting is integrated into German medical practice.<ref>39</ref>
Brachytherapy. For pancreatic cancer, brachytherapy in practice is less common. Nonetheless, Germany has also formally evaluated endoscopic ultrasound–guided injection of 32P-labeled microparticles for unresectable locally advanced pancreatic cancer. The Institute for Quality and Efficiency in Health Care (IQWiG) concluded that the available comparative data were insufficient to determine benefit or harm, and that randomized evidence would be required.<ref>40</ref>

Advanced Radiation

These are technology-intensive modalities, primarily particle therapy, considered for challenging anatomy, re-irradiation scenarios, or clinical trials.

Proton Beam Radiation. Protons can reduce the "exit dose," which is particularly beneficial when a pancreatic tumor is located near radiosensitive bowel tissue.<ref>41</ref> Germany has several centers equipped for proton therapy. A retrospective series from Marburg Ion-Beam Therapy Center reported outcomes in 25 patients with localized nonresectable pancreatic cancer or localized recurrent disease treated with proton chemoradiation. Reported local control was 86% at 6 months and 80% at 12 months. The study concluded that proton therapy for pancreatic cancer in Germany achieved high local control, but that distant metastases remained the primary driver of overall outcomes.<ref>42</ref>
Carbon-Ion Therapy. Carbon ions demonstrate higher biological effectiveness and precise dose shaping, but their availability is limited to select centers.<ref>43</ref> In an experience from Heidelberg involving the treatment of locally recurrent pancreatic cancer with carbon ions, the estimated one-year local control rate was 87.5%, with a median overall survival of 12.7 months in that small patient cohort. This data illustrates the strong potential for local control but also emphasizes that distant metastasis remains a significant risk for many patients.<ref>44</ref>

Interventional Radiology & Oncology

Alongside the mentioned treatment ranges earlier, treatment in Germany for pancreatic cancer can also include image-guided procedures performed by interventional radiology and advanced endoscopy teams. These options are most often used when surgery is not possible (for example, unresectable tumors) or when the main goal is symptom relief, which is common in stage 4 pancreatic cancer treatment in Germany.

In certified German cancer centers, decisions are typically made in tumor boards with multidisciplinary oncology teams, so each patient receives a personalized treatment plan rather than a “one procedure fits all” approach.

Ablation Options

Ablation refers to the process of destroying tumor tissue using a probe, which is a thin, needle-like device. This device is placed into or adjacent to a tumor under imaging guidance, such as CT or ultrasound, and sometimes through endoscopic ultrasound.<ref>45</ref> Common ablation techniques relevant to pancreatic cancer care include:

Irreversible Electroporation. Uses short electrical pulses (not heat) to damage tumor cells. It may be considered when the tumor cannot be safely removed, especially when the cancer is close to major vessels, which is a frequent reason for unresectable tumors.<ref>46</ref> NanoKnife pancreatic cancer therapy in Germany is offered at specialized centers and discussed on a case-by-case basis. Published expert discussions emphasize that the evidence is still developing and that irreversible electroporation should be used in carefully selected patients.<ref>47</ref><ref>48</ref>
Thermal Ablation. Radiofrequency ablation (RFA) or microwave ablation (MWA) may be used to treat a small number of metastases in organs like the liver, typically when disease is limited and a local “spot treatment” makes sense alongside systemic therapy.<ref>49</ref> German university radiology departments describe MWA as a standard interventional option for liver metastases in appropriate candidates.<ref>50</ref>
Cryoablation. Cryoablation is a local treatment that destroys tumor tissue by freezing it (via one or more needle-like probes placed under imaging or intraoperative ultrasound guidance). A German-based data note states that only limited clinical data exist for pancreatic cancer cryoablation and summarizes two series: one study reported a median survival of 350 days, while the other reported a median survival of approximately 5 months.<ref>51</ref><ref>52</ref>

In practical terms, ablation is rarely a “stand-alone remedy” for pancreatic cancer. It is usually considered when a tumor board believes local control could meaningfully help (pain, pressure effects, or control of a small number of lesions) as part of a broader plan.<ref>52</ref>

Embolization Methodics

Embolization treats tumors by blocking their blood supply. A doctor navigates tiny catheters into arteries feeding the tumor (usually in the liver) and then delivers treatment and/or blocks blood flow. Primary methods you may see offered for pancreatic cancer treatment in German hospitals:

Transarterial Chemoembolization. TACE is a high-concentration chemotherapy delivery directly into a tumor’s arterial supply, combined with particles that reduce blood flow.<ref>53</ref>
Radioembolization. SIRT or TARE uses small radioactive microspheres (typically Yttrium-90) that are delivered via the hepatic artery to target and irradiate liver metastases from within.<ref>54</ref>

A study conducted in a university setting in Munich, Germany, evaluated Y-90 radioembolization as a salvage liver-directed treatment for metastatic exocrine pancreatic cancer. The report indicated a median overall survival of 9 months after undergoing radioembolization, with a 1-year survival rate of 24% among the treated patients.<ref>55</ref>

Drainage & Stenting

Interventional Radiology for Pancreatic Cancer These procedures are often the most immediately helpful interventional options because they can rapidly relieve symptoms and allow patients to eat better and/or start or continue cancer treatment.

Biliary Stenting. Endoscopic stent placement can help open the bile duct. According to the German approaches, metal stents tend to have a lower re-occlusion rate than plastic stents and are generally considered the preferred choice in many palliative situations.<ref>20</ref>
Percutaneous Biliary Drainage. If endoscopic access is impossible, such as in cases of tumor-related duodenal narrowing, or if endoscopic attempts fail, the guideline endorses PTCD (percutaneous transhepatic cholangiodrainage) as a viable alternative.<ref>20</ref>
Endoscopic Stent. For patients with non-curable disease and tumor-related obstruction at the stomach outlet/duodenum, the German guideline states that an endoscopic stent can be placed for symptom relief.<ref>20</ref>

The treatments are typical for advanced disease. In stage 4 pancreatic cancer treatment in Germany, drainage and stenting are often described as “quality-of-life interventions.” They can also be medically beneficial by improving nutrition, reducing infection risks associated with blocked bile ducts, and making systemic therapy safer to administer.

Innovative & Experimental Therapies

Germany is a global hub for pancreatic cancer research, often providing access to treatments that are still in clinical trials or not practised in other countries.<ref>56</ref> Here is a list of the most prominent innovative, adjunctive, and experimental therapies currently available or being studied in German medical centers:

MR-Guided Focused Ultrasound. MRgFUS is available at centers such as University Hospital Cologne and University Hospital Bonn.<ref>58</ref><ref>59</ref><ref>60</ref> This technology uses high-intensity ultrasound waves to "cook" and destroy tumor tissue without incisions, guided in real time by MRI.<ref>57</ref>
Regional Chemoperfusion. In advanced cases, surgeons may use "balloon catheters" to temporarily block blood flow above and below the pancreas. This "isolates" the organ, allowing the high-dose chemo to circulate through the tumor without affecting the rest of the body.<ref>61</ref>
Dendritic Cell Therapy. Specialized German clinics use a process in which a patient’s white blood cells are "trained" in a lab to recognize pancreatic cancer antigens, then reinjected into the patient.<ref>62</ref><ref>63</ref> A dendritic cell vaccine for pancreatic cancer in Germany is used onlyas a non-toxic experimental supplement to standard treatment in metastatic pancreatic cancer care.
Cancer Vaccines. German company BioNTech is testing personalized mRNA vaccines (e.g., autogene cevumeran) that "teach" the immune system to recognize specific mutations in an individual’s pancreatic tumor.<ref>64</ref>
Oncolytic Virotherapy. The German Cancer Research Center in Heidelberg is a leader in using engineered viruses, such as the H-1 Parvovirus and modified Measles virus, which selectively target and kill cancer cells while also triggering an immune response.<ref>65</ref><ref>66</ref>
CAR-T Cell Therapy. Experimental trials (such as the ResCPa study at University Hospital Tubingen) are testing T cells engineered to target specific markers, such as CD318 or Claudin 18.2, which are frequently expressed on pancreatic cancer cells.<ref>67</ref><ref>68</ref>
Radionuclide Therapy. For pancreatic neuroendocrine tumors, Germany is a world leader in using Lutetium-177-DOTATATE, a radioactive "smart bomb" that seeks out specific receptors on the cancer.<ref>69</ref>
Hyperthermia. The technique involves heating the tumor tissue to 40°C-44°C (104°F-111°F). In Germany, hyperthermia is rarely used as a standalone treatment but is a potent "sensitizer" for chemotherapy or radiation.<ref>70</ref>

Pancreatic Cancer Care by Stages

In Germany, the “stage” is not just a label. Instead, it tells the team what they can realistically aim for and which tools make sense. In everyday practice, oncologists often talk in practical categories (resectable, borderline resectable, locally advanced, metastatic) because these categories map directly to what surgery, chemotherapy, or interventional procedures can achieve.<ref>71</ref> This matters because, in German registry data, most patients are diagnosed after the disease has already spread. For instance, in the Munich Cancer Registry dataset, about 57% had distant disease at diagnosis.<ref>72</ref>

When considering treatments for pancreatic cancer in Germany, a staged approach is not only practical but also offers greater clarity for patients. This method helps establish realistic expectations for specific groups and clarifies the goals that doctors aim to achieve at each stage of treatment.

Early Stage: Resectable

Early Stage: Resectable Pancreatic Cancer When a pancreatic tumor is called resectable (the lesion that can still be removed entirely), the goal is straightforward: remove it completely and then treat any remaining microscopic disease, so that long-term control and, sometimes, cure are possible.<ref>3</ref> The cancer removal at this stage is done by laparoscopic or robotic pancreatic surgery in different variations. Typically, a Whipple procedure is performed for head tumors, or a distal pancreatectomy is performed for tail tumors. In German real-world data, Whipple surgery was the most common resection type.<ref>9</ref>

The realistic expectation is that the approach will still be intensive: even after a “successful” operation, pancreatic cancer has a known tendency to come back, so specialists usually combine pancreatic cancer operation in Germany with systemic therapy.<ref>3</ref> In the national guideline, adjuvant chemotherapy (post-operative) is explicitly recommended for patients with stages I–III after a resection, because surgery alone is rarely sufficient in the long term.<ref>29</ref> Adjuvant systemic therapy is common: in one large German claims-data analysis, 58.7% of resected patients received adjuvant therapy within 1 year.<ref>31</ref>

What Germany adds, in a very practical way, is experience and structure in high-complexity pancreatic surgery. Outcomes vary across settings, and German health services research using nationwide discharge data shows better results when pancreatic surgery is performed in higher-volume settings.<ref>72</ref> Here, patients can explore which German hospitals are highlighted in the broad European ranking for Whipple surgery.

Borderline Resectable

Borderline resectable pancreatic cancer means the cancer may still be removable, but it sits close to key blood vessels, so surgery is technically harder, and the risk of leaving a microscopic tumor behind is higher. Here, the goal shifts slightly: instead of rushing to the operating room, the realistic plan is often to “earn” a safer, cleaner operation by using treatment upfront to stabilize or shrink the tumor and test how aggressive it behaves. This means German doctors focus on "downstaging" - shrinking the tumor first, so a Whipple procedure becomes possible.<ref>71</ref>

Borderline Resectable Pancreatic Cancer In patient terms, borderline disease is where you most often see neoadjuvant therapy in action. Commonly, intensive regimens such as FOLFIRINOX for fit patients are used, or gemcitabine-based options when a gentler approach is needed.<ref>71</ref> If the tumor becomes operable (sometimes with planned vascular reconstruction), pancreatic surgery is then performed in an experienced center, followed by additional systemic therapy when appropriate.

In Germany, chemotherapy is usually the “engine” that does most of the tumor downsizing in borderline resectable pancreatic cancer, but it is not the only tool German teams use to improve operability. One additional option used in selected German cases is preoperative chemoradiotherapy, which the German S3 guideline explicitly lists as an alternative to preoperative chemotherapy for borderline resectable disease.<ref>71</ref> Some centers also offer stereotactic body radiotherapy using highly precise platforms such as CyberKnife, which is designed to deliver high doses with tight margins while accounting for patient motion; both Charité University Hospital and University Hospital Heidelberg include CyberKnife as part of their high-precision radiotherapy capabilities.<ref>37</ref><ref>74</ref>

Where Germany differs most noticeably from some countries is in surgery, because high-volume pancreatic centers routinely use advanced vessel-focused techniques and reconstructions that expand what “operable” can mean after successful induction therapy. For instance, the European Pancreas Center Heidelberg surgeons may combine venous resections/reconstructions with meticulous clearance of tissue around key arteries rather than automatically declaring the case inoperable.<ref>75</ref>

Two concepts developed in Heidelberg are particularly relevant for borderline resectable tumors. The first is the TRIANGLE operation, which uses an extended dissection strategy to achieve complete clearance within the anatomical "triangle" formed by the major blood vessels. An early report from Germany analyzed 330 patients, including matched cohorts receiving the TRIANGLE approach and standard treatment.<ref>76</ref> The results indicated that the TRIANGLE method showed a stronger signal for oncologic clearance. The second concept is periarterial divestment, a technique that involves the complete removal of soft tissue around the peripancreatic arteries to avoid the need for formal arterial resection.<ref>77</ref>

Stage 3: Locally Advanced Disease

Stage 3: Locally Advanced Pancreatic Cancer Stage three pancreatic cancer means the tumor is still limited to the abdomen (there are no confirmed distant metastases), but it is wrapped around or tightly attached to major blood vessels, so an operation is not safely possible at this time. In other words, the cancer is “locally advanced” and initially unresectable.<ref>78</ref> The main goal of stage 3 pancreatic cancer treatment in Germany is to gain control over the disease with systemic therapy first, keep symptoms manageable, and then repeatedly reassess whether the situation can be converted into a surgery plan for some patients.

The first step is usually a combination chemotherapy, because doctors must treat the cancer as a whole-body illness even when scans show only local disease. The national guideline explicitly recommends combination regimens for borderline resectable and locally advanced tumors (e.g., FOLFIRINOX or gemcitabine + nab-paclitaxel in appropriate patients), since the aim is to shrink or stabilize the tumor and “buy time” against microscopic spread.<ref>71</ref>

What makes Germany distinctive at this stage is the deliberate coordination of the next steps. After a few months of chemotherapy and restaging scans, many patients are discussed again in multidisciplinary oncology teams (tumor boards).<ref>4</ref> If the tumor has not progressed, the recommendations support surgical exploration aimed at secondary resectability.

Even when surgery is still not feasible, centers often add a local-control strategy for carefully selected patients, considering stage 3 pancreatic cancer treatment in Germany. Especially if the tumor remains the dominant problem after chemo. A large German randomized study (CONKO-007) illustrates how this can work in practice: after 3 months of induction chemotherapy, patients without progression were randomized to continue cytostatic drugs or receive chemoradiotherapy.<ref>79</ref> Modern radiotherapy delivery is another area where Germany’s infrastructure can make a difference. A Heidelberg-led randomized phase II program (PARC) used IMRT with a simultaneous integrated boost with systemic agents, and reported that the secondary resection rate differed between trial arms (4% vs 16%).<ref>32</ref>

For some patients, German hospitals may also discuss particle therapy as part of a personalized treatment plan. A Marburg Ion Beam Therapy Center applied pancreatic cancer proton therapy in Germany in non-resectable localized or locally recurrent disease, reporting local control of 86% at 6 months and 80% at 12 months, with a median overall survival of 11.0 months, illustrating the potential strength of protons for local control even though distant spread still drives outcomes.<ref>42</ref>

If the tumor’s location makes surgery impossible, some German hospitals also offer NanoKnife for pancreatic cancer in Germany, so-named irreversible electroporation. It is used in selected cases, typically as a tumor-board decision for unresectable disease near major vessels (the evidence base is evolving, but the technique is part of real-world practice at certain clinics).<ref>48</ref><ref>80</ref>

Metastatic (Stage 4)

When pancreatic cancer is in an advanced situation, so-called stage four, it means the disease has spread beyond the pancreas (most often to the liver, the lining of the abdomen, or the lungs).<ref>81</ref> The main goal of stage four pancreatic cancer treatment in Germany is usually not a cure, but to slow the cancer down, relieve symptoms quickly, and help you stay well enough for ongoing therapy.<ref>29</ref>

Metastatic (Stage 4) Pancreatic Cancer In German certified cancer centers, care is typically coordinated through a multidisciplinary tumor board, so that chemotherapy, symptom-relief procedures, and supportive care are planned together rather than handled “one problem at a time.”<ref>34</ref>

In practice, treatment often starts by confirming the diagnosis and tumor type (most commonly pancreatic adenocarcinoma) through tissue sampling, because treatment choices depend on the cells' appearance and the markers they express. In non-resectable locally advanced or metastatic pancreatic cancer, the German real-world registry and guideline-based courses describe a systemic approach as the main therapy, with histology commonly obtained via endoscopic or image-guided biopsy before chemotherapy begins. For most patients, the backbone of treating stage 4 pancreatic cancer in Germany is systemic therapy. If you are fit enough, German guideline-based care commonly uses combination regimens. If a more intensive regimen is not suitable, gemcitabine-based chemotherapy (often gemcitabine plus nab-paclitaxel) is a standard alternative.<ref>29</ref>

What many patients want to know is what these choices realistically mean. A useful Germany-specific “real-world” reference comes from the prospective Tumour Registry Pancreatic Cancer (TPK) analysis that stratified patients by clinical risk factors. In that German cohort, median overall survival differed substantially by risk group: about 11.4 months in a favourable-risk group, 8.5 months in an intermediate-risk group, and 5.9 months in a poor-risk group, which is one reason German teams emphasise tailoring treatment intensity to fitness and lab markers, rather than just the scan result.<ref>82</ref>

Alongside cancer-directed treatment, pancreatic cancer stage 4 treatment in Germany puts major weight on fast symptom relief, because controlling jaundice, infections, nutrition problems, or pain can directly determine whether you can continue to use further options. For example, biliary obstruction is common in advanced disease; German registry-based discussions note that it occurs in 70–80% of patients with non-resectable pancreatic cancer at some point. The usual first step is not surgery, but drainage, typically endoscopic retrograde cholangiopancreatography (ERCP) with stenting, or a percutaneous drainage route.<ref>19</ref>

Some end-stage patients ask whether anything “local” can be done for metastases, especially when the liver carries most of the tumor burden. These options are typically considered add-ons for selected patients, rather than replacements for chemotherapy for pancreatic cancer stage 4 in Germany. One example is radioembolization for liver metastases. In a Munich experience, objective response in the liver after Y-90 radioembolization was reported in 47% of treated patients.<ref>83</ref>

For patients with only a few metastases, German interventional radiology teams may also discuss thermal ablation (microwave or radiofrequency) for liver lesions when it makes clinical sense, and the anatomy is suitable. While ablation research often includes mixed primary cancers (not only pancreatic), it still demonstrates the local expertise and safety standards in German departments. For instance, a prospective randomized trial from University Hospital Frankfurt compared microwave and radiofrequency ablation for liver metastases and reported no major complications, with a two-year overall survival rate of 70% in that treated cohort.<ref>84</ref> The data that helps explain why ablation is part of the toolset that German tumor boards may consider for selected metastatic pancreatic cancer scenarios.

Where Germany can look different from many countries is access to non-routine, research-driven regional approaches in a handful of specialized centers. One example is regional chemotherapy techniques that use catheter-based methods (including balloon-based flow control concepts) to intensify drug exposure in the upper abdomen.<ref>61</ref> This pancreatic cancer stage 4 treatment in Germany might be a reasonable option to improve the quality of life and terminate disease progression in disseminated malignancy.

If you want the “innovative” layer that you flagged, the country also has a visible footprint in immune-based and virus-based experimental programs. Dendritic cell therapy for pancreatic cancer in Germany is one example. In a pilot study at Ludwig Maximilian University Hospital in Munich, evaluating an autologous dendritic cell vaccine combined with gemcitabine in advanced pancreatic adenocarcinoma, the investigators reported feasibility and safety signals, along with a median overall survival of 10.5 months.<ref>62</ref> The data are encouraging as preliminary research, but not strong enough to be considered a proven standard.

Data, Factors & Treatment Outcomes in Germany

It’s crucial to understand why exactly Germany is highlighted as a top destination. We explore the measurable facts, the pancreatic cancer survival rate in Germany, and other data that showcase the local teams' expertise and system features. Knowing the key figures helps to make an informed decision.

Category	Criterion	Data
Infrastructure	Certified pancreatic cancer centers by the German Cancer Society (DKG)	Germany has approximately 168 certified cancer centers. Certification requires meeting strict annual minimums for surgeries and multidisciplinary tumor board reviews.<ref>85</ref>
	Centralization rate	The percentage of patients treated in certified centers versus general hospitals. In Germany, this is roughly 35-40%, a figure that continues to rise as the health system prioritizes specialized centers for complex surgeries.<ref>85</ref><ref>86</ref>
	Comprehensive cancer centers	Germany maintains a network of 15+ high-end academic hubs that integrate research, surgery, and palliative care under one roof.<ref>87</ref>
Surgical	Minimum volume requirements	German law requires a center to perform at least 20 complex pancreatic resections annually to maintain certification.<ref>6</ref><ref>85</ref> Top-tier hospitals often exceed 200+ resections.
	Robotic & laparoscopic penetration	Recent data from the European E-MIPS registry indicate that approximately 89% to 93% of high-volume certified centers now offer minimally invasive options.<ref>91</ref> In German centers, roughly 58% of all minimally invasive Whipple procedures are now performed robotically.<ref>91</ref> The use of robotic surgery for distal pancreatectomies has risen from approximately 2% to nearly 20%.<ref>93</ref>
	Resection benchmarks	In German DKG-certified centers, the R0 resection rate is consistently high, typically 75%-85%.<ref>85</ref>
	Mortality for Whipple procedures	High-volume German centers maintain mortality rates below 3-5%, significantly lower than often seen in non-specialized hospitals globally.<ref>85</ref><ref>88</ref>
Innovations	Clinical trial scope	There are approximately 150 clinical trials in Germany involving pancreatic cancer.<ref>92</ref>
	Authored, patented methods	Germany is the home of several specialized protocols used in pancreatic cancer: refined vascular reconstruction methods, isolated stop-flow chemoperfusion, LANEX-DC, Traverso-Longmire adaptations for pylorus-preserving pancreaticoduodenectomy, patented mRNA-based vaccine, oncolytic viruses protocols, and transarterial chemo-perfusion.
	Advanced technology access	Germany has one of the highest concentrations of advanced oncological equipment globally, including NanoKnife, carbon-ion therapy, MR-linac, HIFU, etc.
Outcome	5-Year Survival Rates	While the global average remains low, top-tier German centers report post-resection 5-year survival rates of up to 27%, compared to international averages of 15-20%.<ref>89</ref><ref>90</ref>

Best Pancreatic Cancer Hospitals in Germany

Choosing a clinic for complex oncology care is less about general reputation and more about specific technical expertise, high surgical volumes, and access to a broad range of clinical trials.

University hospitals and certified pancreatic cancer treatment centers in Germany are uniquely distinguished by their multidisciplinary "tumor boards," where surgeons, oncologists, and radiologists collaborate to tailor therapy to each patient's molecular tumor profile.

Whether you are seeking high-precision surgical resection or exploring systemic options for advanced-stage disease, these institutions provide the infrastructure for comprehensive diagnostics and holistic care.

Below is an overview of the leading hospitals in Germany, categorized by their specific clinical "stacks" and technical strengths.

Certified Pancreatic Surgery Centers

Here, we selected a recognized pancreatic cancer center in Germany that performed surgical interventions ranging from the Whipple procedure to more personalized techniques. Whether you are looking for a laparoscopic pancreatic operation or robotic performance, it’s the right place to check.

General Oncology Hospitals

The proper treatment strategy begins with a deep understanding of general oncology. Find the best pancreatic cancer hospitals in Germany for systemic treatments, including chemotherapy, palliative care, and targeted therapies.

National Center for Tumor Diseases Heidelberg
Comprehensive Cancer Center Munich
University Hospital Cologne
Helios Hospital Berlin-Buch
University Hospital Frankfurt

Interventional Radiology Units

Below is a brief overview of leading interventional radiology centers in Germany, focusing on what differentiates them in pancreatic cancer care: case volume and technical breadth. Searching for a precise embolization or pancreatic lesion ablation technique? This is the right list of interventional pancreatic cancer treatment centers in Germany to start with.

Institute for Interventional Radiology Frankfurt
University Hospital Magdeburg
University Hospital Regensburg
University Hospital Bonn
University Hospital Leipzig

Radiatocentres with Pancreatic Cancer Expertise

Sometimes the treatment program might require specialized radiation therapy places capable of pancreatic tumor treatment. Explore the vetted German radio centres distinguished in the field.

Heidelberg Ion Beam Therapy Center
West German Proton Therapy Centre Essen
European Radiosurgery Centre Munich
University Hospital Erlangen
University Hospital Charité Berlin

Clinics Offering Innovative Therapies

When standard care is exhausted, and an advanced or experimental approach is needed, such clinics might be the right fit. Treating stage 4 pancreatic cancer in Germany can require these solutions for patients with limited options remaining and progressive disease.

How to Choose the Right Clinic?

Finding the right oncology facility is a complex and highly time-sensitive decision. Before navigating the various pancreatic cancer clinics in Germany, it is crucial to understand your specific medical objectives.

To summarize the key points, consider your primary goal for pancreatic cancer treatment in Germany: Is it a definitive initial diagnosis and staging? Is it a matter of optimizing a systemic chemotherapy regimen? Should it involve advanced molecular profiling for individualized targeted therapy? Are you seeking certified cancer centers for a complex resection, such as the Whipple procedure? Should it be the local tough of the interventional radiologist? Or perhaps the case is quite advanced, and you are looking for new, experimental approaches because standard protocols no longer work? Based on these preliminary inquiries, it makes sense to seek out providers who specialize in your specific stage and clinical situation.

The next step is to gather details about clinics and doctors in Germany. Patients can use Airomedical's clinic search tools or the doctor's sections to find suitable matches. For a more in-depth evaluation, review the profiles of hospitals or doctors, focusing on their credentials, whether pancreatic cancer is their primary focus, and what previous patients have said about their experiences.

Lastly, it is advisable to consider the clinic's location, ensuring it is convenient to travel to, along with any associated costs charged by the selected medical facility.

Pancreatic Cancer Treatment Cost in Germany

Pancreatic cancer care can range from standard outpatient chemotherapy to complex inpatient surgical interventions, depending on the tumor’s stage, its proximity, and whether advanced localized therapies are required. To clarify the pancreatic cancer cost in Germany, we outline the most common treatment methods and procedures used across different clinics. Navigate our offer section for ready-to-go packages.

Modality	Treatment name	Cost
Surgery	Laparoscopic pancreaticoduodenectomy	From €65.000
	Laparoscopic pancreatectomy	From €58.000
	Robotic Whipple procedure	From €80.000
	Palliative surgery	From €25.000
Systhemic	Chemotherapy	€4,500–15,000
	Targeted therapy	€7,000–18,000
	Immunotherapy	€8,000–19,000
Radiation	External-beam radiotherapy	€18,000–50,000
	SBRT (CyberKnife)	€22,000–45,000
	Brachytherapy	€22,000–35,000
	Proton Therapy	From €90.000
	Carbon-Ion Therapy	From €95,000
Interventional	Irreversible Electroporation (NanoKnife)	From €27,000
	Thermal ablation	From €19,000
	Cryoablation	€15,000–24,000
	Transarterial chemoembolization (TACE)	From €30,000
	Radioembolization	From €95,000
	Biliary stenting	From €10,000
	Percutaneous biliary drainage	From €8,500
Experimental	MR-Guided Focused Ultrasound	From €32,000
	Regional chemoperfusion	€35,000–45,000
	Dendritic cell therapy (DCT)	From €19,000
	Cancer vaccines	From €25,000
	Oncolytic virotherapy	€30,000–45,000
	CAR-T cell therapy	From €500.000
	Radionuclide therapy	From €27,000
	Hyperthermia	From €4,000

FAQ

<faq>How to get a second opinion for pancreatic cancer options available in Germany for my case? Send your key records (latest CT/MRI/PET reports and images, pathology/biopsy report, blood tests, including prior treatments). Airomedical then coordinates a German specialist (often within a certified center), arranges a remote review, and provides a second-opinion report with a proposed treatment pathway and a preliminary cost estimate; if needed, they can also organize a follow-up teleconsultation and on-site scheduling.

What is the cost of pancreatic cancer surgery in Germany? Typically €25,000–€80,000, depending on operation type (palliative vs curative, open vs laparoscopic vs robotic), complexity (vessel reconstruction), and length of stay.

Is stage four pancreatic cancer treatment in Germany suitable for international patients? Yes, often, because stage 4 care is multidisciplinary and time-sensitive, and many German university hospitals can coordinate fast diagnostics, systemic therapy, and supportive procedures (stents, drainage, pain control). Suitability mainly depends on performance status, organ function, and whether rapid treatment logistics are feasible.

What pancreatic cancer treatment options in Germany can be offered? A typical German spectrum can include: curative-intent surgery, systemic therapy, biomarker-driven targeted therapy, selected immunotherapy, radiotherapy, interventional oncology, supportive endoscopy, and selected innovative and experimental programs.

What is the pancreatic cancer immunotherapy cost in Germany? In Germany, the cost of pancreatic cancer immunotherapy depends on the type of immunotherapy used. Conventional checkpoint immunotherapy typically costs between €8,000 and €19,000. If a clinic proposes a dendritic cell–based approach, pricing usually starts from €19,000. Personalized cancer vaccine programs generally start from €25,000 and can be significantly higher depending on how individualized the product and protocol are. CAR-T cell therapy is at the highest end.

What is the range applied to the pancreatic cancer cost in Germany? Most standard multi-step oncology pathways (diagnostics + chemo ± procedures) commonly fall in the mid–high five figures, depending on duration and chosen modalities.

What are the 5 best pancreatic cancer hospitals in Germany? High-ranking options include University Hospital Heidelberg, TUM University Hospital Rechts der Isar Munich, Charité Universitätsmedizin Berlin, University Hospital Frankfurt, and University Hospital Cologne. The “best” choice depends on your needs.

What experimental immunotherapy-based options are practised in Germany? Most commonly: dendritic cell therapy (DCT) programs, cancer vaccine trials (including personalized approaches), CAR-T trials (highly selected), and oncolytic virotherapy in research settings; these are usually accessed via trials or specialized clinics rather than routine care.

Is proton therapy for pancreatic cancer in Germany is possbile? Yes. It is available in select centers and typically considered for carefully selected locally advanced/recurrent cases, often within structured protocols.

Is it possible to have classical pancreatic cancer immunotherapy in Germany? Yes, but usually only when the tumor has the right biomarkers (for example, MSI-H/dMMR) or via clinical trials/off-label routes in specialized hospitals.

What is the 4th stage of pancreatic cancer in Germany? It is the same definition as internationally: metastatic disease, meaning the cancer has spread to distant organs (commonly liver, peritoneum, and lungs).

Why is stage 3 pancreatic cancer treatment in Germany different? Because stage 3 is often locally advanced and initially unresectable, German centers frequently focus on induction systemic therapy, high-precision local control where appropriate, and repeated re-evaluation in experienced multidisciplinary teams, including complex vessel-oriented surgical techniques. This can sometimes convert a case to operability.</faq>

References

German Centre for Cancer Registry Data (ZfKD), Robert Koch Institute. Pancreatic cancer. Retrieved January 2026.
Ayres Pereira, M., & Chio, I. I. C. (2020). Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies. Genes, 11(1), 6. doi: 10.3390/genes11010006. Retrieved January 2026.
PDQ Adult Treatment Editorial Board. (2025, February 12). Pancreatic Cancer Treatment (PDQ®)–Health Professional Version. National Cancer Institute. Retrieved January 2026.
Mayerle, J., Reißfelder, C., Wesselmann, S., Rückher, J., Utzig, M., Barth, C., & Dudu, F. (2023, May 3). Jahresbericht der zertifizierten Pankreaskarzinomzentren: Kennzahlenauswertung 2023 (Auditjahr 2022 / Kennzahlenjahr 2021). Deutsche Krebsgesellschaft (DKG) (in Zusammenarbeit mit OnkoZert). Retrieved January 2026.
Gemeinsamer Bundesausschuss (G-BA). Mindestmengen für planbare medizinische Leistungen. Retrieved January 2026.
Gemeinsamer Bundesausschuss (G-BA). (2021, December 16). Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Regelungen gemäß § 136b Absatz 1 Nummer 2 SGB V (Mindestmengenregelungen – Mm-R): Änderung der Nr. 4 der Anlage. Retrieved January 2026.
D’Cruz, J. R., Misra, S., Menon, G., & Shamsudeen, S. (2024, October 6). Pancreaticoduodenectomy (Whipple Procedure). In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Retrieved January 2026.
Leitlinienprogramm Onkologie. (2024, September). S3-Leitlinie Exokrines Pankreaskarzinom: Langversion 3.1 (AWMF-Registernummer: 032-010OL). Retrieved January 2026.
Uttinger, K., Niezold, A., Weimann, L., Plum, P. S., Baum, P., Diers, J., … Wiegering, A. (2024, December 12). Weekday effect of surgery on in-hospital outcome in pancreatic surgery: a population-based study. Langenbeck’s Archives of Surgery, 410, Article 4 (2025). doi: 10.1007/s00423-024-03573-9. Retrieved January 2026.
Loos, M., Mack, C. E., Xu, A. T. L., Hassenpflug, M., Hinz, U., Mehrabi, A., … Büchler, M. W. (2024, March 1). Distal pancreatectomy: Extent of resection determines surgical risk categories. Annals of Surgery, 279(3), 479–485. doi: 10.1097/SLA.0000000000005935. Retrieved January 2026.
Intuitive. Intuitive da Vinci. Retrieved January 2026.
Timmermann, L., Biebl, M., Schmelzle, M., Bahra, M., Malinka, T., & Pratschke, J. (2021, January 11). Implementation of robotic assistance in pancreatic surgery: Experiences from the first 101 consecutive cases. Journal of Clinical Medicine, 10(2), 229. doi: 10.3390/jcm10020229. Retrieved January 2026.
Müller-Debus, C. F., Thomaschewski, M., Zimmermann, M., Wellner, U. F., Bausch, D., & Keck, T. (2020, March 17). Robot-assisted pancreatic surgery: A structured approach to standardization of a program and of the operation. Visceral Medicine, 36(2), 104–112. doi: 10.1159/000506909. Retrieved January 2026.
Liu, R., Abu Hilal, M., Besselink, M. G., Hackert, T., Palanivelu, C., Zhao, Y., He, J., Boggi, U., Jang, J.-Y., Panaro, F., Goh, B. K. P., Efanov, M., Nagakawa, Y., Kim, H.-J., Yin, X., Zhao, Z., Shyr, Y.-M., Iyer, S., Kakiashvili, E., … van Ramshorst, T. M. E. (2024, February 1). International consensus guidelines on robotic pancreatic surgery in 2023. Hepatobiliary Surgery and Nutrition, 13(1), 89–104. doi: 10.21037/hbsn-23-132. Retrieved January 2026.
Hillebrandt, K. H., Knitter, S., Timmermann, L., Felsenstein, M., Benzing, C., Schmelzle, M., Pratschke, J., & Malinka, T. (2021, December 9). Robotic-assisted pancreatic surgery in the elderly patient: experiences from a high-volume centre. BMC Surgery, 21, Article 415. doi: 10.1186/s12893-021-01395-w. Retrieved January 2026.
Perinel, J., & Adham, M. (2019, May 7). Palliative therapy in pancreatic cancer—palliative surgery. Translational Gastroenterology and Hepatology, 4, 28. doi: 10.21037/tgh.2019.04.03. Retrieved January 2026.
Balogun, O. S., & Atoyebi, O. A. (2022, October 6). Management of malignant obstructive jaundice: Defining the relevance of various palliative surgical options in resource-challenged settings: A review article. Journal of the West African College of Surgeons, 12(3), 111–119. doi: 10.4103/jwas.jwas_22_22. Retrieved January 2026.
Jambor, M. A., Ashrafizadeh, A., Nahm, C. B., et al. (2022, October 11). The role of staging laparoscopy in pancreatic adenocarcinoma and its effect on patients’ survival. World Journal of Surgical Oncology, 20, 337. doi: 10.1186/s12957-022-02803-y. Retrieved January 2026.
Hofmann, F. O., Miksch, R. C., Weniger, M., et al. (2022, November 11). Outcomes and risks in palliative pancreatic surgery: an analysis of the German StuDoQ|Pancreas registry. BMC Surgery, 22, 389. doi: 10.1186/s12893-022-01833-3. Retrieved January 2026.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). (2024, September). S3-Leitlinie Exokrines Pankreaskarzinom: Langversion 3.1 (AWMF-Registernummer: 032-010OL). Retrieved January 2026.
Wainberg, Z. A., Melisi, D., Macarulla, T., Pazo Cid, R., Chandana, S. R., De La Fouchardière, C., et al. (2023, October 7). NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet, 402(10409), 1272–1281. doi: 10.1016/S0140-6736(23)01366-1. Retrieved January 2026.
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., et al. (2013, October 31). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine, 369(18), 1691–1703. doi: 10.1056/NEJMoa1304369. Retrieved January 2026.
National Cancer Institute. (2022, May 31). Targeted Therapy to Treat Cancer. Retrieved January 2026.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). (2024, March). S3-Leitlinie Exokrines Pankreaskarzinom: Langversion 3.0. Retrieved January 2026.
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O’Reilly, E. M., McGuinness, D., Cui, K. Y., Schlienger, K., Locker, G. Y., & Kindler, H. L. (2019, July 25). Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. New England Journal of Medicine, 381(4), 317–327. https://doi.org/10.1056/NEJMoa1903387. Retrieved January 2026.
Reissig, T. M., Tzianopoulos, I., Liffers, S.-T., Rosery, V. K., Guyot, M., Ting, S., Wiesweg, M., Kasper, S., Meister, P., Herold, T., Schmidt, H. H., Schumacher, B., Albers, D., Markus, P., Treckmann, J., Schuler, M., Schildhaus, H.-U., & Siveke, J. T. (2023, June). Smaller panel, similar results: Genomic profiling and molecularly informed therapy in pancreatic cancer. ESMO Open, 8(3), 101539. https://doi.org/10.1016/j.esmoop.2023.101539. Retrieved January 2026.
Hartupee, C., Nagalo, B. M., Chabu, C. Y., Tesfay, M. Z., Coleman-Barnett, J., West, J. T., & Moaven, O. (2024, February 1). Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target. Frontiers in Immunology, 15, 1287459. https://doi.org/10.3389/fimmu.2024.1287459. Retrieved January 2026.
Maru, S. Y., & Jaffee, E. M. (2024, October 28). Pancreatic cancer is feeling the heat. Journal for ImmunoTherapy of Cancer, 12(10), e010124. https://doi.org/10.1136/jitc-2024-010124. Retrieved January 2026.
Leitlinienprogramm Onkologie. (2024, September). S3-Leitlinie Exokrines Pankreaskarzinom: Langversion 3.1 – September 2024 (AWMF-Registernummer: 032-010OL). Retrieved January 2026.
Leitlinienprogramm Onkologie. (2021, December). S3-Leitlinie zum exokrinen Pankreaskarzinom: Kurzversion 2.0 – Dezember 2021 (AWMF-Registernummer: 032/010OL). Retrieved January 2026.
Damm, M., Heinig, M., Rosendahl, J., Michl, P., Haug, U., & Krug, S. (2025, September 19). Trends in the Treatment and Survival of Pancreatic Cancer: Analysis of 23,339 Patients Diagnosed Between 2010 and 2017. Cancer Medicine, 14(18), e71248. https://doi.org/10.1002/cam4.71248. Retrieved January 2026.
Liermann, J., Münter, M., Naumann, P., Abdollahi, A., Krempien, R., & Debus, J. (2022, March 9). Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial. Clinical and Translational Radiation Oncology, 34, 15–22. https://doi.org/10.1016/j.ctro.2022.03.003. Retrieved January 2026.
Buchele, C., Renkamp, C. K., Regnery, S., Behnisch, R., Rippke, C., Schlüter, F., … Klüter, S. (2024, June 25). Intrafraction organ movement in adaptive MR-guided radiotherapy of abdominal lesions – dosimetric impact and how to detect its extent in advance. Radiation Oncology, 19(1), 80. https://doi.org/10.1186/s13014-024-02466-x. Retrieved January 2026.
Deutsche Krebsgesellschaft (DKG). (2018, July 22). Erhebungsbogen für Viszeralonkologische Zentren der Deutschen Krebsgesellschaft (Vers. I1; 22.07.2018). Retrieved January 2026.
Benedict, S. H., Yenice, K. M., Followill, D., Galvin, J. M., Hinson, W., Kavanagh, B., … Yin, F.-F. (2010, August). Stereotactic body radiation therapy: The report of AAPM Task Group 101. Medical Physics, 37(8), 4078–4101. https://doi.org/10.1118/1.3438081. Retrieved January 2026.
Broggi, S., Passoni, P., Tiberio, P., Cicchetti, A., Cattaneo, G. M., Longobardi, B., Mori, M., Reni, M., Slim, N., Del Vecchio, A., Di Muzio, N. G., & Fiorino, C. (2023, January 24). Stomach and duodenum dose–volume constraints for locally advanced pancreatic cancer patients treated in 15 fractions in combination with chemotherapy. Frontiers in Oncology, 12, 983984. https://doi.org/10.3389/fonc.2022.983984. Retrieved January 2026.
Universitätsklinikum Heidelberg. Stereotaxie am Cyberknife. Retrieved January 2026.
Charité – Universitätsmedizin Berlin, Department of Radiation Oncology and Radiotherapy. Charité Cyberknife Center. Retrieved January 2026.
Roeder, F., Timke, C., Uhl, M., Habl, G., Hensley, F. W., Buechler, M. W., Krempien, R., Huber, P. E., Debus, J., & Werner, J. (2012, July 18). Aggressive local treatment containing intraoperative radiation therapy (IORT) for patients with isolated local recurrences of pancreatic cancer: a retrospective analysis. BMC Cancer, 12, Article 295. https://doi.org/10.1186/1471-2407-12-295. Retrieved January 2026.
Institute for Quality and Efficiency in Health Care (IQWiG). (2022, January 24). Endoscopic ultrasound-guided implantation via injection of 32P-labeled microparticles for unresectable, locally advanced pancreatic cancer: Extract of assessment according to §137h SGB V (H21-13, Version 1.0). IQWiG Reports (Commission No. H21-13). Retrieved January 2026.
Kobeissi, J. M., Simone, C. B., II, Lin, H., Hilal, L., & Hajj, C. (2022, June 4). Proton Therapy in the Management of Pancreatic Cancer. Cancers, 14(11), 2789. https://doi.org/10.3390/cancers14112789. Retrieved January 2026.
Lautenschlaeger, S., Dumke, C., Exeli, L., Hauswald, H., Engenhart-Cabillic, R., & Eberle, F. (2023, July 10). Treatment of primary or recurrent non-resectable pancreatic cancer with proton beam irradiation combined with gemcitabine-based chemotherapy. Strahlentherapie und Onkologie, 199(11), 982–991. https://doi.org/10.1007/s00066-023-02106-5. Retrieved January 2026.
Mohamad, O., Sishc, B. J., Saha, J., Pompos, A., Rahimi, A., Story, M. D., Davis, A. J., & Kim, D. W. N. (2017, June 9). Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage/Repair. Cancers, 9(6), 66. https://doi.org/10.3390/cancers9060066. Retrieved January 2026.
Liermann, J., Ben-Josef, E., Syed, M., Debus, J., Herfarth, K., & Naumann, P. (2021, August 5). Carbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer. Strahlentherapie und Onkologie, 198, 378–387. https://doi.org/10.1007/s00066-021-01827-9. Retrieved January 2026.
Ahmed, M., Solbiati, L., Brace, C. L., et al. (2014, June 13). Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria—A 10-Year Update. Radiology, 273(1), 241–260. https://doi.org/10.1148/radiol.14132958. Retrieved January 2026.
Gajewska-Naryniecka, A., Szwedowicz, U., Łapińska, Z., Rudno-Rudzińska, J., Kielan, W., & Kulbacka, J. (2023, February 23). Irreversible Electroporation in Pancreatic Cancer—An Evolving Experimental and Clinical Method. International Journal of Molecular Sciences, 24(5), 4381. https://doi.org/10.3390/ijms24054381. Retrieved January 2026.
Heger, U., Mack, C., Tjaden, C., Pan, F., Pausch, T., Hinz, U., Sommer, C. M., & Hackert, T. (2021, August 12). Open irreversible electroporation for isolated local recurrence of pancreatic ductal adenocarcinoma after primary surgery. Pancreatology, 21(7), 1349–1355. https://doi.org/10.1016/j.pan.2021.08.002. Retrieved January 2026.
Vos, D. J. W., Ruarus, A. H. R., Timmer, F. E. F., Geboers, B., Bagla, S., Belfiore, G., Besselink, M. G., et al. (2024, July 10). Consensus Guidelines of Irreversible Electroporation for Pancreatic Tumors: Protocol Standardization Using the Modified Delphi Technique. Seminars in Interventional Radiology, 41(2), 176–219. https://doi.org/10.1055/s-0044-1787164. Retrieved January 2026.
Crocetti, L., de Baére, T., Pereira, P. L., & Tarantino, F. P. (2020, May 7). CIRSE Standards of Practice on Thermal Ablation of Liver Tumours. CardioVascular and Interventional Radiology, 43, 951–962. https://doi.org/10.1007/s00270-020-02471-z. Retrieved January 2026.
Universitätsklinikum Frankfurt, Institut für Diagnostische und Interventionelle Radiologie. Mikrowellenablation. Retrieved January 2026.
Geboers, B., Ruarus, A. H., Nieuwenhuizen, S., Puijk, R. S., Scheffer, H. J., de Gruijl, T. D., & Meijerink, M. R. (2019, December 27). Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation by in vivo vaccination? Chinese Clinical Oncology, 8(6). https://doi.org/10.21037/cco.2019.10.05. Retrieved January 2026.
Narayanan, G., Daye, D., Wilson, N. M., Noman, R., Mahendra, A. M., & Doshi, M. H. (2021, May 21). Ablation in Pancreatic Cancer: Past, Present and Future. Cancers, 13(11), 2511. https://doi.org/10.3390/cancers13112511. Retrieved January 2026.
RadiologyInfo.org (RSNA, ACR, & ASRT). (2024, September 16). TACE Cancerous Tumor Therapy. Retrieved January 2026.
RadiologyInfo.org (RSNA, ACR, & ASRT). (2023, September 10). Radioembolization (Y90). Retrieved January 2026.
Michl, M., Haug, A. R., Jakobs, T. F., Paprottka, P., Hoffmann, R.-T., Bartenstein, P., Boeck, S., Haas, M., Laubender, R. P., & Heinemann, V. (2014, January 1). Radioembolization with Yttrium-90 Microspheres (SIRT) in Pancreatic Cancer Patients with Liver Metastases: Efficacy, Safety and Prognostic Factors. Oncology, 86(1), 24–32. https://doi.org/10.1159/000355821. Retrieved January 2026.
ClinicalTrials.gov. Search results: Pancreatic Cancer (Germany). Retrieved January 2026.
Leporace, M., Calabria, F. F., Siciliano, R., Capalbo, C., Filippiadis, D. K., & Iezzi, R. (2025). The Thermal Ablation with MRgFUS: From Physics to Oncological Applications. Cancers, 17(1), 36. https://doi.org/10.3390/cancers17010036. Retrieved January 2026.
Focused Ultrasound Foundation. (2025, March 18). Pancreatic cancer: Two focused ultrasound clinical trials have begun in Germany. Retrieved January 2026.
German Clinical Trials Register (DRKS). (2025, July 21). Evaluation of Sonalleve MR-HIFU for Ablation of Locally Advanced Non-resectable and Metastatic Pancreatic Cancer in Patients with Non-progressive Disease under First-line Chemotherapy: Feasibility and Safety Clinical Study (HIFU-PANC). Retrieved January 2026.
German Clinical Trials Register (DRKS). (2024, February 13). Prospective, single-center, randomized, two-arm, open phase I/II study on feasibility, safety and efficacy of local treatment with high intensity focused ultrasound (HIFU) in combination with standard chemotherapy in patients with inoperable pancreatic cancer (HIFU-PC15). Retrieved January 2026.
Aigner, K. R., Gailhofer, S., Selak, E., … Aigner, K. (2019, September 10). Intra-arterial infusion chemotherapy versus isolated upper abdominal perfusion for advanced pancreatic cancer: a retrospective cohort study on 454 patients. Journal of Cancer Research and Clinical Oncology, 145, 2855–2862. https://doi.org/10.1007/s00432-019-03019-6. Retrieved January 2026.
Bauer, C., Dauer, M., Saraj, S., Schnurr, M., Bauernfeind, F., … Eigler, A. (2011, May 6). Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study. Cancer Immunology, Immunotherapy, 60, 1097–1107. https://doi.org/10.1007/s00262-011-1023-5. Retrieved January 2026.
Sprooten, J., Ceusters, J., Coosemans, A., Agostinis, P., De Vleeschouwer, S., et al. (2019, July 18). Trial watch: dendritic cell vaccination for cancer immunotherapy. Oncoimmunology, 8(11), e1638212. https://doi.org/10.1080/2162402X.2019.1638212. Retrieved January 2026.
Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., … Balachandran, V. P. (2023, May 10). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature, 618(7963), 144–150. https://doi.org/10.1038/s41586-023-06063-y. Retrieved January 2026.
German Cancer Research Center (DKFZ). Virotherapy. Retrieved January 2026.
Hajda, J., Leuchs, B., Angelova, A. L., Frehtman, V., Rommelaere, J., Mertens, M., … Ungerechts, G. (2021, October 15). Phase 2 trial of oncolytic H-1 parvovirus therapy shows safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma. Clinical Cancer Research, 27(20), 5546–5556. https://doi.org/10.1158/1078-0432.CCR-21-1020. Retrieved January 2026.
Arbeitsgemeinschaft Internistische Onkologie (AIO). (2025, October 7). ResCPa study: Response features, efficacy and safety of CD318-targeted CAR-T cell therapy against pancreatic cancer. Retrieved January 2026.
ClinicalTrials.gov. (2025, September 3). CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (NCT07153289). Retrieved January 2026.
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., … NETTER-1 Trial Investigators. (2017, January 12). Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. New England Journal of Medicine, 376(2), 125–135. https://doi.org/10.1056/NEJMoa1607427. Retrieved January 2026.
Datta, N. R., Kok, H. P., Crezee, H., & Bodis, S. (2020, June 12). Integrating loco-regional hyperthermia into the current oncology practice: SWOT and TOWS analyses. Frontiers in Oncology, 10, 819. https://doi.org/10.3389/fonc.2020.00819. Retrieved January 2026.
Leitlinienprogramm Onkologie. (2024, September). S3-Leitlinie Exokrines Pankreaskarzinom: Kurzversion 3.1 (AWMF-Registernummer: 032-010OL). Retrieved January 2026.
Munich Cancer Registry (MCR). (2022, April 15). ICD-10 C25: Pancreas cancer — Survival (Year of diagnosis 1998–2020). Retrieved January 2026.
Krautz, C., Nimptsch, U., Mansky, T., & Grützmann, R. (2019). Volume-outcome effects in pancreatic surgery in Germany – an observational study of hospital discharge data. HPB, 21(Suppl 3), S980. https://doi.org/10.1016/j.hpb.2019.10.1294. Retrieved January 2026.
Charité – Universitätsmedizin Berlin. CyberKnife technology. Retrieved January 8, 2026.
Schneider, M., Strobel, O., Hackert, T., & Büchler, M. W. (2019, November 14). Pancreatic resection for cancer—the Heidelberg technique. Langenbeck's Archives of Surgery, 404(8), 1017–1022. https://doi.org/10.1007/s00423-019-01839-1. Retrieved January 2026.
Klotz, R., et al. (2022). The TRIANGLE operation for pancreatic head and body cancers: early postoperative outcomes. HPB (Oxford), 24(3), 332–341. https://doi.org/10.1016/j.hpb.2021.06.432. Retrieved January 2026.
Diener, M. K., et al. (2021). Periarterial divestment in pancreatic cancer surgery. Surgery, 169(5), 1019–1025. https://doi.org/10.1016/j.surg.2020.08.030. Retrieved January 2026.
van Veldhuisen, E., van den Oord, C., Brada, L. J., Walma, M. S., Vogel, J. A., Wilmink, J. W., del Chiaro, M., van Lienden, K. P., Meijerink, M. R., & van Tienhoven, G. (2019, July 12). Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Cancers, 11(7), 976. https://doi.org/10.3390/cancers11070976. Retrieved January 2026.
Fietkau, R., Ghadimi, M., Grützmann, R., Wittel, U. A., Jacobasch, L., Uhl, W., Croner, R. S., Bechstein, W. O., Neumann, U. P., Waldschmidt, D., Boeck, S., Moosmann, N., Reinacher-Schick, A. C., Golcher, H., Adler, W., Semrau, S., Lubgan, D., Kallies, A., Hecht, M., Tischoff, I., Tannapfel, A., Frey, B., Oettle, H., & CONKO Study Group. (2025, August 13). Benefit of chemoradiotherapy versus chemotherapy after induction therapy for conversion of unresectable into resectable pancreatic cancer: The randomized CONKO-007 trial. Journal of Clinical Oncology, 43(30), 3266–3278. https://doi.org/10.1200/JCO-24-01502. Retrieved January 2026.
TUM Klinikum Rechts der Isar, Sektion für Interventionelle Radiologie. Irreversible Elektroporation im Pankreas. Retrieved January 2026.
PDQ Adult Treatment Editorial Board, National Cancer Institute. (2025, May 16). Pancreatic Cancer Treatment (PDQ®)–Patient Version. Retrieved January 2026.
Marschner, N., Hegewisch-Becker, S., Reiser, M., von der Heyde, E., Bertram, M., Hollerbach, S. H., Kreher, S., Wolf, T., Binninger, A., Chiabudini, M., Kaiser-Osterhues, A., Jänicke, M., & TPK-Group (Tumour Registry Pancreatic Cancer). (2023, February 1). FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world. International Journal of Cancer, 152(3), 458–469. https://doi.org/10.1002/ijc.34271. Retrieved January 2026.
Michl, M., Haug, A. R., Jakobs, T. F., Paprottka, P., Hoffmann, R.-T., Bartenstein, P., Boeck, S., Haas, M., Laubender, R. P., & Heinemann, V. (2014). Radioembolization with Yttrium-90 Microspheres (SIRT) in Pancreatic Cancer Patients with Liver Metastases: Efficacy, Safety and Prognostic Factors. Oncology, 86, 24–32. https://doi.org/10.1159/000355821. Retrieved January 2026.
Vogl, T. J., Jaraysa, Y., Martin, S. S., Gruber-Rouh, T., Savage, R. H., Nour-Eldin, N. A., & Mehmedovic, A. (2022, January 28). A prospective randomized trial comparing microwave and radiofrequency ablation for the treatment of liver metastases using a dual ablation system ─ The Mira study. European Journal of Radiology Open, 9, 100399. https://doi.org/10.1016/j.ejro.2022.100399. Retrieved January 2026.
European Cancer Certification (ECC). (2025). Annual Report of the Certified Pancreatic Cancer Centres: Indicator Analysis 2025 (Audit Year 2024 / Indicator Year 2023). Retrieved January 2026.
Emmert, M., Gorodiscan, M., Thater, C., et al. (2024, November 22). Quality-assured treatment in certified cancer center networks in upper Franconia, Germany: a population-centered retrospective cohort analysis based on data of the Bavarian cancer registry. BMC Health Services Research, 24, 1453. https://doi.org/10.1186/s12913-024-11972-3. Retrieved January 2026.
CCC-Netzwerk der Deutschen Krebshilfe. Onkologische Spitzenzentren. Retrieved January 2026.
Bliss, L. A., Yang, C. J., Chau, Z., Ng, S. C., McFadden, D. W., Kent, T. S., Moser, A. J., Callery, M. P., & Tseng, J. F. (2014, October). Patient selection and the volume effect in pancreatic surgery: unequal benefits? HPB (Oxford), 16(10), 899–906. https://doi.org/10.1111/hpb.12283. Retrieved January 2026.
Kleeff, J., Reiser, C., Hinz, U., Bachmann, J., Debus, J., Jaeger, D., Friess, H., & Büchler, M. W. (2007, April). Surgery for recurrent pancreatic ductal adenocarcinoma. Annals of Surgery, 245(4), 566–572. https://doi.org/10.1097/01.sla.0000245845.06772.7d. Retrieved January 2026.
Strobel, O., Lorenz, P., Hinz, U., Gaida, M., König, A.-K., Hank, T., … Büchler, M. W. (2022, May). Actual five-year survival after upfront resection for pancreatic ductal adenocarcinoma: Who beats the odds?. Annals of Surgery, 275(5), 962–971. doi: 10.1097/SLA.0000000000004147. Retrieved January 2026.
van der Heijde, N., Vissers, F. L., Boggi, U., Dokmak, S., Edwin, B., Hackert, T., … Abu Hilal, M. (2021, April). Designing the European registry on minimally invasive pancreatic surgery: A pan-European survey. HPB, 23(4), 566–574. doi: 10.1016/j.hpb.2020.08.015. Retrieved January 2026.
European Union Clinical Trials Register. Clinical trials for pancreatic cancer (Germany search results). Retrieved January 2026.
Weksler, Y., Lifshitz, G., Avital, S., & Rudnicki, Y. (2025). Robotic surgery for gastrointestinal malignancies—A review of how far have we come in pancreatic, gastric, liver, and colorectal cancer surgery. Cancers, 17(23), 3802. doi: 10.3390/cancers17233802. Retrieved January 2026.

</reflinks>